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Abstract
Purpose of Review To best support all patients with inherited cancer risk, we must broaden our scope of practice to consider 
the needs of the transgender and gender diverse (trans) community. We considered best practice for supporting trans patients 
including tailored risk assessments and management recommendations.
Recent Findings There is limited literature considering trans patient care in cancer genetics. Small case studies have high-
lighted how medical transition and cancer risk–reducing options intersect with the need for individualised care. Studies have 
also shown that cancer genetics professionals do not feel prepared to support trans patients.
Summary Patient-centred care for trans patients relies on a multidisciplinary team (MDT) engaged in shared decision-
making. National guidelines are needed to standardise access to appropriate discussions around risk-reducing options and 
screening. International collaborative research is required to provide empiric data on the impact of gender-affirming treat-
ments on cancer risk, and more experiential data is needed from trans patients accessing cancer genetics services. Finally, 
education and training in this area should be formally embedded for all cancer genetics professionals.
Keywords Cancer risk · Transgender · Genetics · Personalised care
Introduction
Across UK cancer genetics services, an increase in referrals for 
transgender and gender diverse (trans) patients with inherited 
cancer risk has been observed. This mirrors the rise in demand 
for Gender Identity Clinic (GIC) services in the UK [1, 2].
A transgender person is someone whose gender is differ-
ent from their sex assigned at birth. They may have under-
gone medical transition which can include taking sex-related 
hormones and gender-affirming surgeries. Gender is not a 
static binary of male or female, and trans people may iden-
tify their gender using other descriptors, for example non-
binary, instead of or in addition to terms typically perceived 
as binary. Gender is fluid and may change for people over 
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time. Many trans people experience trans gender dyspho-
ria, a specific distress caused by an incongruence between 
one’s gender identity and one’s own and/or other people’s 
gendered perceptions of one’s body and other sex/gender 
signifiers [3••].
In many clinical specialities, transgender status may not 
alter the appropriate clinical approach, and the assumption 
that it does can diminish the quality of care. However, in 
cancer genetics, trans patients may have different needs from 
cisgender patients presenting with a similar family history. 
These needs may arise from the impact of medical transition 
on cancer risk, or from psychosocial factors associated with 
genetic testing. These include, but are not limited to, gen-
der dysphoria, challenging family communication, timing 
of testing and the potential exacerbation of risks by stress.
In fast-changing fields like cancer genetics, and young 
specialities like gender identity healthcare, ongoing research 
is crucial in supporting patients appropriately. Sutherland 
et al. have summarised considerations in hereditary breast 
and gynaecological cancers, highlighting a common theme: 
a series of unanswered questions [4•]. Considering trans-
inclusive genetic counselling, some guidance is available 
around cultural competency, inclusive pedigree symbols 
and practice recommendations [3••]. There has also been 
some consideration of the experience of genetic counsellors 
seeing trans patients [5, 6]; however, there is minimal litera-
ture containing experiences from the patients’ perspective 
beyond one study by Barnes et al. [7••]. The majority of 
literature is from a US perspective and does not reflect all 
aspects of the experience of trans patients in the UK.
Here, we consider the experiences and management of 
trans patients accessing UK cancer genetics services. We 
provide a background to gender identity care in the UK 
and discuss a series of cases highlighting the needs of trans 
patients with inherited cancer risk, including a direct patient 
perspective. We outline recommendations for cancer genet-
ics clinicians seeing trans patients, and the clinicians who 
refer them. Finally, we outline the further work required to 
improve cancer genetics services for these patients.
Gender Identity Care in the UK
Patients may choose to access transition-related care through 
either the NHS or private routes, or a mixture of both.
Within the NHS, there are seven adult Gender Identity 
Clinics (GICs): two in Scotland and one in Wales. These 
can be accessed by GP referral. These are staffed by medi-
cal doctors and psychologists and make recommendations 
around suitability for gender-affirming hormonal therapies, 
surgeries and other interventions and may also offer speech 
and language therapy and/or counselling psychology [8]. In 
addition, a number of gender service pilots were announced 
in England in 2020 [9–12]. Adults currently on the waiting 
list for a GIC will be able to access hormones, and in some 
cases, surgical referrals, more rapidly through this route. 
Some clinics also have further services on-site, such as 
trans-specific sexual health.
The NHS Gender Identity Development Service (GIDS) 
assesses children with suspected gender dysphoria and has 
bases in London and Leeds, as well as outreach clinics in 
other major cities.
There are currently long waiting lists for NHS GICs and 
GIDS, where patients can wait over 3 and a half years from 
referral [13]. There are also long gaps between appointments 
[14]. Patients may therefore access hormones via the inter-
net to self-medicate [15, 16]. GPs may or may not provide 
clinical oversight of this depending on expertise and patient 
disclosure. GPs can also choose to provide “bridging” hor-
mone prescriptions prior to assessment by a GIC if they feel 
the psychological and harm-reduction benefits outweigh any 
risks. However, despite clear guidance [17], many refuse, 
due to lack of experience or training, fear of litigation or 
outright transphobia.
A list of gender affirming treatments that may be accessed 
by trans patients can be found in Table 1. Note that non-
binary patients, as well as some trans feminine and trans 
masculine people may choose to access both masculinising 
and feminizing treatments [18].




Currently, NHS healthcare information systems ask for only 
male or female “gender” at registration. There is no approved 
Information Standard for gender identity or transgender sta-
tus monitoring [19], though at the time of writing, this is 
being developed by LGBT Foundation, CliniQ, Action for 
transgender Health and National LGB&T Partnership based 
on the questions used by the HIV and AIDS Reporting Data 
Set [20].
This creates a number of barriers to care. Patients are 
unlikely to want to engage with a service that demonstrates 
ignorance about their medical history and fails to recognise 
their identity. This can impair rapport with genetics profes-
sionals. Patients may choose not to disclose their transgen-
der status and be given inaccurate advice. In addition, if we 
fail to collect data on our trans population, we will fail to 
detect trends in both their clinical outcomes and the quality 
of their care.
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Stigma and Microaggressions
Stonewall [21] reported that 41% of trans people experi-
enced healthcare staff who lacked understanding of their 
specific health needs, and 7% had been refused access to 
healthcare. Trans patients may be less likely to engage 
with a range of healthcare services due to fear of dis-
crimination [22]. This is exacerbated in the field of genet-
ics where informational and awareness-raising materials 
rarely use gender neutral terms, with practices that can 
be based on cisnormative and heteronormative assump-
tions [23].
Experiences from the Cancer Genetics and Gender Identity 
Clinic
Cancer family histories raise complex issues around indi-
vidual risk, screening and preventative options, as well as 
patient choice. No two patient experiences are the same, 
but shared lessons can be learned from individual stories. 
The following vignettes have been anonymised or fabri-
cated using a combination of cases from the authors’ (BC, 
AB and JG) clinical experiences, to highlight the needs of 
trans patients with a family history of cancer.
Case 1: Dysphoria in the Cancer Genetics Clinic
Clinical Scenario
A 28-year-old transgender man was referred to genetics by 
his GIC at 50% risk of a familial BRCA1 pathogenic vari-
ant. He was taking testosterone and considering bilateral 
mastectomy with male chest reconstruction.
Identified Issues
• Discussions around breasts/ovaries and dysphoria
• Chest tissue and cancer risk
• Ovarian cancer risk
Recommended Management
While dysphoria is not experienced by all trans patients, 
clinicians should be aware of the potential impact of cancer 
genetics discussions on gender incongruence. Using gender 
neutral anatomical terms may alleviate this, for example 
‘chest’, when discussing breast cancer with transgender men.
Appropriate screening and surgical options should be 
discussed with BRCA carriers who were assigned female 
at birth. Most, but not all, male chest reconstructions leave 
Table 1  Gender-affirming treatment options available through NHS and private healthcare
Effect Treatment or intervention Types NHS funded




5-alpha reductase inhibitor Tablet No
Progesterone Tablet No
Genital reconstructive surgery Vaginoplasty Yes
(some other surgery types also 
available privately)
Vulvoplasty
Facial hair removal Laser Country and region-dependent
Electrolysis
Breast augmentation Various available No
Facial feminisation Various available No
Cricothyroid shave n/a No
Masculinising Testosterone Injection Yes
Gel
GnRHa Injection Yes
Bilateral mastectomy and male chest reconstruction n/a Yes
Total abdominal hysterectomy and bilateral salpingo-
oophorectomy (TAH and BSO)
n/a Yes
Genital reconstructive surgery Phalloplasty Yes
Metoidioplasty
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some remaining breast tissue [24], and so would provide 
less cancer risk reduction. However, complete mastectomy 
with lipofilling would be a viable alternative. This would be 
expected to provide risk reduction comparable to cisgender 
women who undergo bilateral mastectomy with autologous 
reconstruction.
Not all transgender men will choose to undergo mastec-
tomy [25], and most who do will retain breast tissue. In this 
case, an MDT approach should be used to work with screen-
ing units to consider the most appropriate screening methods 
that minimise dysphoria. Mammography will not be possible 
on a patient who has undergone male chest reconstruction, 
and so, annual MRIs are more appropriate and are less likely 
to exacerbate dysphoria.
As with chest surgery, choices around total abdominal 
hysterectomy and bilateral salpingo-oophorectomy (TAH 
and BSO) vary between patients. Clinicians should avoid 
assumptions about patients’ surgery choices. Instead, shared 
decision-making [26] should be used to consider which 
options are best for the patient given their cancer risk, tran-
sition and preferences about fertility preservation.
Case 2: The Impact of Hormones on Cancer Risk
Clinical Scenario
A 32-year-old non-binary BRCA2 carrier did not express 
that their gender was incongruent with the male sex they 
were assigned at birth when taken through predictive testing. 
After this, they began taking oestrogen ordered online for 
feminization to minimise dysphoria and were re-referred to 
genetics by their GIC.
Identified Issues
• Oestrogen and breast cancer risk
• Prostate cancer risk and associated dysphoria
Recommended Management
There is a lack of data regarding the impact of oestrogen on 
breast cancer risk in trans patients. De Blok et al. compared 
breast cancer cases in transgender women taking oestrogen 
and cisgender men [27]. They found a 47-fold increase in 
breast cancer incidence and a younger age of onset, though 
still 3 times less than the incidence in cisgender women. 
This study included trans women who had taken oestrogen 
across a range of time frames and did not include informa-
tion on cancer family history for most patients, except one 
known BRCA1 carrier. More data are needed to elucidate 
effects of oestrogen on breast cancer risks in those with a 
family history.
In transgender women, oestrogen is typically dosed to 
achieve levels in pubertal female range lifelong [28, 29]. 
Therefore, breast cancer risk in trans patients may be 
reduced by lowering oestrogen to a maintenance dose after 
5 years, the average timeframe to achieve the desired femini-
sation. A non-binary person may also wish to do this or may 
choose a lower dose throughout depending on the degree of 
feminisation they wish to achieve.
Clinicians may be uncomfortable knowing the patient is 
self-medicating with oestrogen. Clinicians should employ a 
patient-centred approach acknowledging how both continu-
ing or stopping hormones could have health implications 
either upon cancer risk, or risk of dysphoria and/or harass-
ment and resultant stress-related mental and physical health 
problems. In this situation, the genetics service could sup-
port a patient to seek a bridging prescription from their GP.
Transgender patients assigned male at birth who are 
BRCA2 carriers will not have their prostate removed if they 
undergo genital surgery so these patients should be offered 
prostate screening [30]. The patient should be informed of 
the screening process so they can prepare for this, and an 
MDT approach should be taken to minimize the impact of 
dysphoria. It may be appropriate to refer to specialist clinics 
with experience of prostate cancer screening in transgender 
patients, as a digital prostate exam may be more challenging 
due to atrophy.
Case 3: Timing of Genetic Testing
Clinical Scenario
A 20-year-old transgender woman was referred to genet-
ics at 50% risk of a familial BRCA2 pathogenic variant. At 
this time, predictive testing was secondary to her desire to 
begin hormone treatment. After thorough discussion, she 
decided not to pursue predictive testing and felt she may 
consider this closer to age 30. In the following year, she 
began hormone therapy. However, within a few months, she 
re-contacted the genetics service distressed. She stated that 
the GIC wished to know her BRCA2 status before increas-
ing her dose of oestrogen. She was then seen for further 
discussion in the genetics clinic, and again chose to delay 
her predictive testing. In addition to being several years from 
the age of risk significantly increasing, she reflected on how 
she might struggle to cope with a result at this stage of her 
life, being relatively early within her transition, a university 
student and experiencing the fallout of breast cancer and 
BRCA2 testing in her family.
Identified Issues
• Breast and prostate cancer risks
• Timing of risk-reducing surgery and hormone treatment
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• Inherited cancer risk as a barrier to accessing hormones
• Lack of communication between genetics services and a 
GIC
Recommended Management
As discussed above, providing this patient with an accurate 
breast cancer risk assessment following gender-affirming 
hormone treatment is difficult, with her risk of prostate can-
cer similar to cis male BRCA2 carriers. Here, as above, all 
surgery and risk-reducing options should be discussed with 
the patient during their genetics appointment.
There are currently no formal guidelines for surgical man-
agement of transgender BRCA carriers. This case raises a 
potential argument for risk-reducing mastectomy and recon-
struction prior to starting hormone therapy in appropriate 
circumstances. Such an approach has the benefit of negating 
much of the cancer risk related to breast growth on oestrogen 
while allowing the patient to experience its other effects. 
Breast reconstruction in itself may reduce dysphoria. This 
option was not discussed with the patient as the genetic ser-
vice had not connected with the local GIC to consider this, 
highlighting the importance of an MDT approach.
The choice to pursue predictive testing is complex for 
many young adults [31], irrespective of the psychosocial 
complexities of gender transition. Real or perceived pressure 
from a GIC can lead to patients undergoing genetic testing 
against their true wishes, for fear of losing access to gen-
der affirming treatment [6]. Similarly, declining to undergo 
genetic testing might be used, wholly inappropriately, as a 
barrier to treatment, as described above. It is unethical for 
genetic testing to be a prerequisite, but it is important that 
patients have all the relevant information about risks and 
benefits before starting gender affirming treatment [32]. In 
cases such as this, (and where the risk of a variant is identi-
fied by the GIC) a suitable approach may be a referral to 
clinical genetics for a dedicated discussion.
Case 4: It is Not All About BRCA 
Clinical Scenario
A 40-year-old transgender woman was seen in the GIC. 
She had a history of confirmed familial adenomatous poly-
posis (FAP) caused by a pathogenic APC variant. She had 
undergone prophylactic colectomy and had developed an 
abdominal wall desmoid tumour. She wished to access gen-
der-affirming hormones and genital surgery. She also wished 
to discuss her options for fertility preservation as she had not 
wanted to pass on her condition and was aware she may be 
eligible for pre-implantation diagnosis (PGD).
Identified Issues
• Inherited cancer risk and gender-affirming treatment 
interactions outside of BRCA 
• Desmoid tumour risk from oestrogen and gender affirm-
ing surgery
• Reproductive considerations
• Requirements for MDT approach
Recommended Management
One in five with FAP develop desmoid tumours [33]. Their 
growth can be driven by oestrogen, and in cisgender popula-
tions, anti-oestrogen therapy may be effective in up to 50% 
of cases [34]. The GIC clinician should seek advice from 
specialists including cancer geneticists, gastroenterologists 
or surgeons working in FAP and their local endocrinologist 
in order to gather the information to appropriately discuss 
risks and benefits of oestrogen with the patient. It may be 
useful to conduct a mini-MDT meeting or involve the other 
clinicians in a single patient consultation.
If the patient is happy to accept the risk of a growing 
desmoid, then they should be commenced at the lowest dose 
of oestrogen (as is usual practice) and monitored with regu-
lar imaging as per the specialists’ recommendations [28]. 
Any increase in dose will be a joint decision between the 
patient and the GIC considering blood results and moni-
toring imaging. It is important to acknowledge the uncer-
tainty here given the lack of research. One strategy, as in 
the BRCA2 case above, might be to aim for female range 
oestradiol levels for the first 5 years to enable anatomical 
changes and then to consider lowering the dose of oestrogen, 
to reduce the risk of further desmoid development.
In patients without a desmoid, the risks of develop-
ment would still need to be discussed and regular imaging 
undertaken.
As desmoids tend to develop at sites of previous sur-
gery, genital reconstruction surgery also presents additional 
risks and may not achieve the desired cosmetic outcome. 
Importantly, the diagnosis of FAP with or without desmoid 
tumours should not prevent a patient receiving a referral, 
but the surgeon should be made aware of the history. Previ-
ous colectomy or current desmoids may make surgeries, in 
particular vaginoplasty, too technically difficult, and this is 
a surgical decision.
Regardless of gender identity, sexual orientation or any 
diagnosis, one should not make assumptions about future 
wishes for biological children. This patient is eligible for 
PGD in England, since FAP is on the Human Fertilisation 
and Embryology Authority eligibility list [35]. Gender-
affirming hormone regimens typically suppress fertility, 
and while this suppression is reversible in a proportion of 
individuals (by stopping the hormone treatment), it is not yet 
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possible to make any predictions in individual cases [36]. 
Trans patients may also access surgeries that remove the 
gonads, causing irreversible infertility. They are therefore 
eligible for gamete storage under the HFEA guidelines [37]. 
This should be offered prior to commencing hormones but 
remains an option later, though the patient may struggle with 
dysphoria from stopping hormones. It should be noted that 
eligibility for NHS funding for storage and fertility treat-
ments varies by devolved nation, and by clinical commis-
sioning group in England.
Finally, a diagnosis of FAP necessitates interaction with 
other specialities and departments, e.g. imaging and endos-
copy, who may not have the same level of training and cul-
tural competency. Genetics clinicians should explore how 
the patient found their interactions with these departments 
as they are unlikely to want to engage with the recommended 
screening if they are met with discrimination or a lack of 
consideration. It may be necessary to contact the depart-
ments in question to provide education or indeed to raise 
concerns if needed.
Case 5: The Need for Tissue‑Specific Guidance
Clinical Scenario
Figure 1 pedigree showing a 45-year-old transgender woman 
who was referred from the breast cancer family history clinic 
where both herself and her 42-year-old cousin were seen. No 
genetic testing was carried out in the family, and they were 
not eligible for NHS testing. She had been on oestrogen for 
the last 5 years and had GRS a year ago.
Identified Issues
• Considering risk in families without a known inherited 
cancer risk syndrome
• National screening guidance is not inclusive of trans 
patients
Recommended Management
Patients with a family history of breast cancer with no 
known inherited cause are currently recommended breast 
screening based on NICE CG164 guidance, which does not 
clarify considerations for trans patients [38].
Basing screening guidance on a person’s individual can-
cer risk in (a) specific tissue/s would be more inclusive for 
trans patients and increase equity in the quality of care 
patients receive. However, more data are needed to ade-
quately assess lifetime cancer risks in trans patients with 
an inherited risk. Until such data are available patients 
should be counselled on a case-by-case basis, supporting 
informed decision-making around appropriate screening 
for each individual. Transgender women, like the above 
patient (Fig. 1), should be offered the same breast screen-
ing as cisgender women with an equivalent family history. 
However, they should be informed that their lifetime risks 
will likely be lower, given available data [27].
Case 6: The Impact of Transition on Family Systems
Clinical Scenario
A 63-year-old woman was referred to genetics following 
an endometrial cancer diagnosis and was found to carry an 
MLH1 pathogenic variant which causes Lynch syndrome. 
This is an inherited cause of bowel, endometrial, ovarian 
and some other cancers. In clinic, the patient explained she 
had a 40-year-old child who had been assigned female at 
birth and was in the process of transitioning. The patient 
used a range of pronouns and different names for their 
child, and expressed discomfort with their transition, 
explaining that consequently, they were no longer in regu-
lar contact.
Identified Issues
• Endometrial and ovarian cancer risks in Lynch syndrome
• Potential impact of transition on family communications
Fig. 1  Pedigree showing a 45-year-old transgender woman who was 
referred from the breast cancer family history clinic where both her-
self and her 42-year-old cousin were seen. She has been on oestrogen 
for the last 5 years and has had GRS.
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Recommended Management
As with previous cases, there are some transition-specific 
cancer risks to consider in Lynch syndrome. If a trans per-
son is taking testosterone, there are concerns that this may 
increase endometrial cancer risk due to endometrial thicken-
ing [27] though evidence is conflicting. It is therefore impor-
tant to discuss risk-reducing TAH and BSO if this had not 
already been performed as part of gender affirming surgery.
Challenging family relationships are not unusual in can-
cer genetics, and breakdowns in family communications are 
reported for a variety of reasons. This case highlights the 
impact of familial support and rejection of trans people [39, 
40]. Standard practice, such as “dear relatives” letters passed 
through mutual connections, can support communication, 
and ethics committee discussions may be relevant where this 
is not possible. It is also important to consider that a patient 
may not have disclosed their transgender status to their fam-
ily, and so, as is common when working with families in 
genetics, confidentiality is key.
Trans patients, and especially those who have experi-
enced familial rejection, may have a ‘chosen family’. These 
provide a crucial support network and should be considered 
when assessing patients’ support through their genetic test-
ing process (Box 1).
Box 1: The patient perspective
“There was a lack of mental support at the early stages 
of transition when I was coping with this and my genetic 
diagnosis. I was offered psychological support, however 
due to a long waiting list with a waiting time of 3 years 
the biggest problems of my transition had to be solved 
alone so I could start living a normal life.
Another big issue was my partner was not offered any 
psychological support. Patient’s partners must deal with 
complete changeover of their feelings. In some ways they 
must grieve their partner in order to be able to live with 
a new one – their transgender partner. Due to my genetic 
condition, my partner and I were entitled to PGD which 
we had started to undertake. My transition took a toll on 
my partnership and it did not survive. Although we are 
still very close we are no longer a couple and PGD treat-
ment was cancelled.
There is often a lack of communication between doctors 
and the GIC. I was constantly advised to speak to my 
GIC clinicians directly, which felt odd as my assumption 
was that the GP would have quicker access to a relevant 
person from the gender clinic than myself. Since I have 
other health issues, I was afraid that a lack of adequate 
hormonal treatment could lead to serious damage to my 
body, causing my dysphoria to be experienced more 
severely. Fortunately, my leading doctor linked my case 
with an oncologist who also specialised in gender identity 
problems.
I strongly believe that establishing the MDT would help 
these issues and many people in a similar situation would 
not have to go through the same rocky path as I have had 
to go through.”
Good Practice for Cancer Genetics Clinicians
The complex intersection of medical, cultural, ethical and 
psychosocial aspects of care is present for all patients taken 
through genetic testing. It is the role of the cancer genetics 
clinician to develop their cultural competencies to meet the 
needs of their patients. Von Vaupel-Klein and Walsh have 
provided a detailed account of cultural competency consid-
erations for genetic counsellors seeing transgender patients 
that should be used alongside the guidance here [3••].
The genetics clinic appointment should provide a space 
where patients feel comfortable to talk about their gender 
identity and disclose information about their transition-
ing process. Clinicians should remember that all patients’ 
choices around gender differ. Figure 2 shows an infographic 
summary of key considerations for good practice in cancer 
genetics.
Good Practice for Clinicians Referring 
to Cancer Genetics
Clinicians who are likely to refer trans patients to clinical 
genetics include family history nurses, GPs, gender iden-
tity specialists, oncologists and possibly other members 
of the cancer care team. They may encounter patients at 
various stages of their transition, which might have differ-
ent implications for their interaction with the patient, and 
the immediacy of their referral. In Fig. 3, we provide an 
infographic summary of key considerations for referral to 
cancer genetics.
Next Steps
Several steps are needed for genetics services to provide 
an equally high standard of care for all patients, regardless 
of gender modality [41]. There is a stark need for further 
research across many areas to make accurate risk assess-
ments and provide appropriate recommendations. Robust 
data are needed on the impact of medical transition and soci-
oeconomic risk factors on cancer risks for trans patients with 
inherited cancer predisposition. Furthermore, it is impor-
tant that the experiences of trans patients seen by cancer 
genetics services are collected and reviewed to identify 
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Fig. 2  Good practice guidance 
for cancer genetics clinicians
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Fig. 3  Good practice guidance 
for clinicians referring to cancer 
genetics
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areas for service improvement. Similarly, the attitudes and 
experiences of genetics professionals in the UK should be 
examined. Such research is necessary to identify and remove 
barriers to genetics services, and to create a safe and com-
fortable environment for trans patients.
Studies have shown that more than 80% of genetic coun-
selling and medical students did not receive training on trans 
health issues [6, 42]. These studies are limited by small sam-
ple sizes [42] and lack of focus on UK genetic counselling 
curricula [6]. However, these figures are alarming, espe-
cially the finding that only 8% of UK oncologists felt confi-
dent in their knowledge of the specific healthcare needs of 
LGBT + cancer patients (43). To equip future clinicians with 
the knowledge and skills to ensure equally high standards 
of care, it is imperative that their curricula adequately cover 
topics relevant to trans patients, including, but not limited 
to, cultural competencies. To ensure professionals maintain 
these skills, ongoing training for clinicians is required.
Beyond this, reviews of current services are needed to 
guide the implementation of improvement and national guid-
ance to ensure genetics services are unbiased and acces-
sible, and practice is inclusive. Such wide-scale work is 
most likely to succeed with international collaboration and 
support from national organisations, such as the UK Can-
cer Genetics Group and Genomic Medicine Service Alli-
ances, and through the formation of a national MDT for trans 
patients with cancer and inherited cancer risk.
Conclusion
In conclusion, the provision of high-quality equitable care 
for trans patients with inherited cancer risk will require a 
personalised approach of genetics and non-genetics clini-
cians alike. It is only by learning from each other, and fore-
most from our patients, that we can better meet their needs.
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